Clearance Summary
Sodium Chloride Inhalation Solution, USP 0.9%, 3% & 7% received FDA 510(k) clearance under submission number K232523, sponsored by Mankind Pharma Limited. The device was reviewed via the Traditional premarket notification pathway and assigned to the Anesthesiology review panel. The statutory decision date of record is 2024-04-10.
- Submission: K232523
- Applicant / Sponsor: Mankind Pharma Limited
- Clearance pathway: Traditional
- Review panel: Anesthesiology
- Device class: Class II
- Regulation citation: 21 CFR 868.5630
- Decision date: 2024-04-10
Classification & Regulation
This clearance is catalogued under FDA product code CAF and 21 CFR 868.5630, within the Anesthesiology review panel as a Class II device.